Investment Rating - The report maintains an "Accumulate" rating for the company [5] Core Views - The company is expected to achieve a net profit attributable to shareholders of 21-31.5 million yuan in 2025, marking a turnaround from losses in previous years [1] - The recovery in the prices of photoinitiators and improved performance quarter by quarter are highlighted, with significant price increases for key products such as TPO, 907, and 184, which rose by 14.7%, 18.1%, and 21.2% respectively [2] - The company is enhancing its industry leadership through the trial production of new photoinitiator projects, which will improve product variety and self-sufficiency in upstream intermediates [3] - The profit forecast for 2025-2027 has been revised upwards, with expected net profits of 31 million, 78 million, and 136 million yuan respectively [3] Summary by Sections Financial Performance - The company anticipates a revenue of 1.513 billion yuan in 2025, with a slight growth of 1.64% year-on-year [4] - The gross profit margin is projected to improve to 15.1% in 2025, up from 8.8% in 2023 [10] - The earnings per share (EPS) is expected to turn positive at 0.19 yuan in 2025, compared to a loss of 0.86 yuan in 2023 [8] Profitability and Valuation - The report indicates a significant improvement in profitability, with a return on equity (ROE) expected to reach 1.2% in 2025, compared to -3.7% in 2023 [10] - The price-to-earnings (P/E) ratio is projected to be 140 in 2025, decreasing to 32 by 2027, indicating a potential for valuation improvement as earnings grow [11] Market Position and Growth - The company is solidifying its market position with new projects entering trial production, which will enhance its capacity and product offerings in the photoinitiator sector [3] - The establishment of the Tianjin Ruiwu Equity Investment Fund is expected to contribute positively to the company's investment income [2]

Core Viewpoint - The company has successfully entered the trial production phase of its Hunan Hongrun Chemical Technology Co., Ltd. project, which is expected to enhance its profitability and competitive edge in the light initiator market [1] Group 1: Project Details - The project involves the construction of an 8,000 tons/year light initiator H4 ketone project, which has passed expert review and is now in trial production [1] - The first phase of the project will produce 5,446.4 tons of cyclohexanecarboxylic acid, an intermediate for H4 ketone production [1] Group 2: Strategic Importance - The project aligns with the company's strategy to achieve a full industry chain integration from toluene to finished products, enhancing its market positioning in light initiators [1] - The successful implementation of this project is expected to further improve the company's profitability and overall competitiveness in the industry [1]

Core Viewpoint - The company, Jiu Ri New Materials (久日新材), has announced the commencement of trial production for two significant projects in the chemical sector, indicating a strategic expansion in its production capabilities [1]. Group 1: Project Announcements - The company has received expert approval for the trial production plan of its subsidiary Hunan Hongrun Chemical Technology Co., Ltd.'s "8000 tons/year photoinitiator H4 ketone project" (Phase I), which has now entered the trial production stage [1]. - The trial production plan for the "Shandong Jiu Ri Chemical Technology Co., Ltd.'s 18340 tons/year photopolymer materials and photoresist intermediates project" has also been approved by experts, and it is currently in the trial production phase [1].

Core Viewpoint - The company has approved the use of part of its raised funds, amounting to 50 million RMB, to provide a loan to its subsidiary, Hunan Hongrun Chemical Technology Co., Ltd., for the implementation of a project to produce 8,000 tons/year of photoinitiator H4 ketone [1][5]. Fundraising Overview - The company raised a total of 1,854.1574 million RMB through its initial public offering, with a net amount of 1,840.6713 million RMB after deducting issuance costs [1]. - The funds will be allocated to various projects, including the Hunan Hongrun project, which is part of a total investment plan of 2,155.5025 million RMB [2]. Loan Details - The loan to Hunan Hongrun will be provided in installments based on the project's construction schedule and actual funding needs, with a maximum term of 36 months [3][4]. - The interest rate for the loan will be determined based on the latest Loan Prime Rate (LPR) and the company's actual debt financing costs [3][4]. Purpose and Impact of the Loan - The loan aims to ensure the smooth implementation of the fundraising investment project and aligns with the planned use of raised funds, without altering the intended use or harming shareholder interests [5]. - Hunan Hongrun is a stable subsidiary with controllable financial risks, which supports the rationale for the loan [5]. Fund Management Post-Loan - The funds will be managed through a dedicated account at Hunan Hongrun, with a tripartite supervision agreement involving the company, a commercial bank, and the sponsor institution [6]. - The management of the funds will comply with relevant regulations and the company's fundraising management system [6]. Opinions from Supervisory Bodies - The supervisory board agrees that the loan aligns with the needs of the fundraising investment project and does not change the intended use of the funds, thus protecting the interests of the company and its shareholders [6]. - The sponsor institution has no objections to the loan arrangement, confirming compliance with regulatory requirements [6].